A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects.

Trial Profile

A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Darotropium bromide (Primary) ; Vilanterol (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 02 Jul 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov.
    • 26 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top